Ongoing investigations into gene therapy to elevate FGF21 activity in humans consider it a promising therapeutic approach for the treatment of type 2 diabetes (DM2) and obesity. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.